Navigation Links
Ben-Gurion U. and Fox Chase Cancer Center awarded NIH measles grant
Date:4/18/2013

PHILADELPHIA April 18, 2013 American Associates, Ben-Gurion University of the Negev (AABGU) announces that Ben-Gurion University of the Negev (BGU) and Fox Chase Cancer Center (FCCC) in Philadelphia have received a two-year National Institutes of Health (NIH) research grant to observe "the role of host encoded microRNAs in the maintenance of the measles virus persistent state."

Many viruses are known to persist in their target cells and establish chronic infection, long after resolution of their acute phase. A thorough understanding of this interplay between viruses and their host may offer insight into the mechanistic basis of human infectious diseases.

This research collaboration is part of an ongoing agreement between BGU and FCCC to support and facilitate scientific and clinical exchanges, as well as to encourage collaborations and joint research between scientists and physicians. Fox Chase and Ben-Gurion formalized their relationship in 2008, but it actually began in 2003 as a partnership spearheaded by AABGU's National Vice President Alton I. Sutnick.

Sutnick, founder of the Health Sciences and Academic Affiliations Committee of AABGU's Mid-Atlantic Region, is a physician and former dean of the Medical College of Pennsylvania (now the Drexel University School of Medicine). Through this partnership, he sought to explore the genetic risks of cancer and incorporate these factors into clinical practice across cultural settings.

"Thanks to Dr. Sutnick and AABGU's Philadelphia chapter, BGU has a longstanding research partnership with Fox Chase that has greatly contributed to medical science," explains Doron Krakow, AABGU executive vice president. "It is a great accomplishment to receive this NIH grant and we look forward to their findings."


'/>"/>

Contact: Andrew Lavin
andrewlavin@alavin.com
516-944-4486
American Associates, Ben-Gurion University of the Negev
Source:Eurekalert

Page: 1

Related biology news :

1. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
2. Sleep deprivation may reduce risk of PTSD according to Ben-Gurion U. researchers
3. Ben-Gurion University of the Negev receives $450,000 grant to conduct oil and natural gas research
4. Preeclampsia poses a significant long-term health risk according to new research from Ben-Gurion U.
5. Ben-Gurion University team in prestigious DARPA Robotics Challenge to develop disaster response robot
6. Ben-Gurion U. establishes stem cell research fund in honor of inventor Jordan Baruch
7. Ben-Gurion U. researchers and Teva Pharmaceutical Industries Ltd. develop psoriasis drug
8. Obama calls Ben-Gurion U. brain research a great idea
9. Navigating the Patent Minefield of Embryonic Stem Cell Product Development; Free Kindle Fire Tablet and Research Database with Purchase
10. Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
11. Embryonic development protein active in cancer growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: